MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.

Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion

Voxelotor CYP and Transporter Cocktail Interaction Study

First Posted Date
2023-08-08
Last Posted Date
2024-11-22
Lead Sponsor
Pfizer
Target Recruit Count
44
Registration Number
NCT05981365
Locations
🇺🇸

ICON Early Phase Services, LLC, San Antonio, Texas, United States

Sodium Chloride vs. Glucose Solute as a Volume Replacement Therapy During Decongestion in Acute Heart Failure

Phase 3
Completed
Conditions
Acute Heart Failure
Heart Failure
Congestion
Interventions
Drug: Continous intravenous infusion of 0.9% Sodium Chloride solution
Drug: Continous intravenous infusion of 5% Glucose solution
First Posted Date
2023-07-27
Last Posted Date
2024-06-21
Lead Sponsor
Wroclaw Medical University
Target Recruit Count
50
Registration Number
NCT05962255
Locations
🇵🇱

Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Lower Silesia, Poland

Diuretic Efficacy of Aminophylline and Furosemide Combination vs Furosemide Alone in Critically Ill Adults

Phase 2
Recruiting
Conditions
Acute Kidney Injury
Interventions
First Posted Date
2023-07-06
Last Posted Date
2023-07-11
Lead Sponsor
University of Malaya
Target Recruit Count
132
Registration Number
NCT05933642
Locations
🇲🇾

University of Malaya, Kuala Lumpur, Malaysia

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser

Phase 3
Not yet recruiting
Conditions
Kidney Stone
Interventions
First Posted Date
2023-06-23
Last Posted Date
2023-11-15
Lead Sponsor
University Hospital, Tours
Target Recruit Count
374
Registration Number
NCT05916963

Diuretic Use in Hemodialysis Patients With Residual Renal Function

Phase 4
Suspended
Conditions
End Stage Renal Disease on Dialysis
Interventions
First Posted Date
2023-06-22
Last Posted Date
2025-03-25
Lead Sponsor
University of Alberta
Target Recruit Count
34
Registration Number
NCT05915286
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study

Phase 4
Completed
Conditions
Chronic Heart Failure
Congestive Heart Failure
Diuretics Drug Reactions
Interventions
First Posted Date
2023-06-15
Last Posted Date
2024-05-21
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
42
Registration Number
NCT05904808
Locations
🇮🇱

Rambam MC, Haifa, Israel

Pragmatic Research on Diuretic Management in Early BPD Pilot

Phase 4
Recruiting
Conditions
Bronchopulmonary Dysplasia
Interventions
Drug: Placebo (plus placebo electrolyte solution)
First Posted Date
2023-06-12
Last Posted Date
2025-04-03
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
30
Registration Number
NCT05898022
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States

🇺🇸

RTI International, Durham, North Carolina, United States

and more 1 locations

Combination Diuretic Therapy for Acute Decompensated Heart Failure

Phase 4
Withdrawn
Conditions
Acute Decompensated Heart Failure
Interventions
First Posted Date
2023-05-03
Last Posted Date
2023-05-03
Lead Sponsor
Ochsner Health System
Registration Number
NCT05840536
Locations
🇺🇸

Ochsner Heart and Vascular Institute, New Orleans, Louisiana, United States

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Interventions
Other: F18-rhPSMA-7.3
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
First Posted Date
2023-03-22
Last Posted Date
2024-07-03
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT05779943
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory Johns Creek Hospital, Johns Creek, Georgia, United States

and more 1 locations

The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation

Phase 3
Not yet recruiting
Conditions
COPD Exacerbation
Chronic Obstructive Pulmonary Disease Exacerbation
Interventions
Drug: Normal saline
First Posted Date
2023-03-15
Last Posted Date
2023-03-15
Lead Sponsor
American University of Beirut Medical Center
Target Recruit Count
200
Registration Number
NCT05769738
© Copyright 2025. All Rights Reserved by MedPath